Hallmarks of 'BRCAness' in sporadic cancers

By N. Turner, Andrew Tutt, Alan Ashworth. Nature Reviews. Cancer, 2004

1,659 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/4a4fa0fc89d74e1280a5f017eba569fecdd4568a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

Citations in the corpus

PARP Inhibitors: The First Synthetic Lethal Targeted Therapy (2017, background): “The term “BRCAness” has been used to describe tumors that have not arisen from a germline BRCA1 or BRCA2 mutation (gBRCAm) but nonetheless share certain phenotypes, in particular an HRR defect, with these hereditary cancers (34, 35).”
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? (2005, background): “As predicted by the hormone receptor and HER2-negative nature of these tumors, most women with BRCA1 mutations generally develop basal-like breast cancer.(8,28) In the Carolina Breast Cancer Study, 20% of the tumors were basal-like.”
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data (2012, methodology): “For example, we used the gene search filter to identify all altered Fanconi Anemia genes [another family of genes involved in the HR pathway (9)] and identified low frequency alterations in FANCA (altered in 3.”
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016, background): “A number of studies have suggested that some sporadic TNBC may bear substantial similarities to BRCA1/2-mutated cancers, including harboring DNA repair defects that might predispose to platinum sensitivity (1, 10, 11).”
Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment (2019, background): “Most BRCA1-related tumors are basal-like (91), and there is a marked resemblance in phenotype and biology between sporadic basal-like tumors and BRCA-associated cancers (90).”
BRCA1 dysfunction in sporadic basal-like breast cancer (2007, background): “We hypothesized that the phenotypic overlap of BRCA1 familial cancers and sporadic basal-like cancers (Foulkes et al., 2003; Sorlie et al., 2003; Lakhani et al., 2005) implied that sporadic basal-like cancers might have an underlying defect in BRCA1-related pathways (Turner et al., 2004).”
Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer (2010, background): “Tumors that are BRCA1 deficient are most commonly basal-like TNBC [53, 54].”
Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. (2009, background): “BRCA1-associated breast tumors have a distinctive pathology and usually express markers of the basal subtype (Foulkes 2004; Turner et al. 2004).”
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. (2006, background): “Sporadic breast (11-14%) and ovarian (5-31%) cancers have been shown to inactivate the BRCA1 gene by methylation (41).”